Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy

NCT00693329 is registered in ClinicalTrials.gov with Abbott RDx Cardiometabolic as lead sponsor.

NCT NCT00693329
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00693329 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Neutrophil Gelatinase-associated Lipcalin(NGAL): A Novel Blood Marker for Determining the Risk of Developing Contrast-Induced Nephopathy
Lead sponsor
Abbott RDx Cardiometabolic
Phase
Observational
Overall status
Completed
Start date
March 31, 2008
Completion date
December 31, 2009
Enrollment
260 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular surgery with coronary angiography